Search
Research
Linkage of the Australian Childhood Immunisation Register (ACIR) and state-based registers to evaluate and inform Australia’s immunisation programChristopher Hannah Tom Blyth Moore Snelling MBBS (Hons) DCH FRACP FRCPA PhD OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Centre
Research
Moort Vax Waangkiny: Understanding reasons for routine vaccine uptake among Aboriginal children aged <5 years in Perth (Boorloo) metroAboriginal children aged younger than 5 years in Perth (Boorloo) have lower vaccine uptake compared to non-Aboriginal children.
Research
Paediatric Active Enhanced Diseases Surveillance (PAEDS)PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.
Research
Post tuberculosis disabilityKefyalew Alene BSc, MPH, PhD Head, Geospatial and Tuberculosis 0404705064 Kefyalew.alene@thekids.org.au Honorary Research Fellow Dr Kefyalew Alene
Research
Spatiotemporal patterns of drug susceptible and drug resistant tuberculosis in Hunan Province, ChinaInvestigators: Kefyalew Alene, Archie Clements External collaborators: Kerri Viney, Dr Darren J Gray (Australian National University) Zuhui Xu (
Research
A retrospective population-based cohort study identifying target areas for prevention of acute lower respiratory infections in childrenAcute lower respiratory infections (ALRI) are a major cause of hospitalisation in young children
Research
Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of
Research
The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second boosterPICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Research
Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of ageFrom 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.
This tool is designed to help current and future parents and caregivers as well as health care providers. It is currently based on the 2025 Western Australian RSV immunisation program.